Recent highlights and breakthroughs in immunotherapy for head and neck cancers - PubMed
5 days ago
- #immunotherapy
- #head and neck cancer
- #clinical trials
- Recent advances in immunotherapy for head and neck cancers highlighted in 2025 studies.
- Key trials include KEYNOTE-689 and NIVOPOSTOP evaluating pembrolizumab and nivolumab in SCCHN.
- DIPPER and DIAMOND trials show promise for camrelizumab and toripalimab in nasopharyngeal carcinoma.
- C-POST trial explores avelumab with cetuximab in cutaneous squamous cell carcinoma.
- Pembrolizumab combined with dabrafenib and trametinib effective in BRAF V600E-mutated anaplastic thyroid carcinoma.
- Passive immunotherapy shows activity in R/M-SCCHN with agents like petosemtamab and amivantamab.
- Antibody-drug conjugates like becotatug vedotin and iza-bren effective in pretreated nasopharyngeal carcinoma.
- Immunotherapy benefits observed earlier in disease course and in combination therapies targeting resistance.